• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, October 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

AMP issues best practice guidelines for next-generation sequencing-based oncology panel validation

Bioengineer by Bioengineer
March 22, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

BETHESDA, Md. — March 22, 2017 — The Association for Molecular Pathology (AMP), the premier global, non-profit molecular diagnostics professional society, today published consensus recommendations to help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients. The report, "Guidelines for Validation of Next Generation Sequencing (NGS)-based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists," was released online ahead of publication in the Journal of Molecular Diagnostics.

"In this era of precision medicine, NGS has quickly become the method of choice for detecting multiple somatic variants, diagnosing disease, and predicting response to targeted therapies. However, the required analytical validation process remains challenging," said Lawrence Jennings, MD, PhD, Attending Pathologist, Ann and Robert H. Lurie Children's Hospital of Chicago, Working Group Chair, and AMP Member. "AMP convened and led a multidisciplinary subject matter expert working group with liaison representation from CAP to summarize current knowledge, expose challenges, and provide guidance on how to best validate these tests to ultimately improve patient care."

AMP is in the process of providing a series of guidelines designed to improve the entire NGS workflow. The joint consensus recommendations are based on evidence from a review of published literature, empirical data, current laboratory practice surveys, feedback from multiple public meetings, and expert professional experiences. The latest report addresses NGS test development, optimization and familiarization, and best practices for establishing test performance characteristics. The recommendations emphasize the critical role of the molecular laboratory director in establishing and utilizing an error-based approach for patient risk management. Since these recommendations represent current best practice in a rapidly developing field, AMP anticipates a need for ongoing updates. The new report follows the previously published guidelines on interpreting oncology sequence variants. AMP plans on publishing the next companion paper in this series focusing on downstream NGS bioinformatics analysis later this year.

"With this series of guidelines, AMP continues to provide the cancer genomics community with the appropriate tools and guidance to better incorporate the latest scientific breakthroughs and technological innovations in molecular pathology," said Marina N. Nikiforova, MD, Professor of Pathology at University of Pittsburgh Medical Center, Working Group Member, and 2016 AMP Clinical Practice Committee Chair. "Our hope is that we will soon see the widespread adoption of these guidelines leading to improvements in how molecular pathologists validate and provide high-quality NGS results to support our oncologists, pathologists, and most importantly, patients."

###

To read the full manuscript, please visit http://dx.doi.org/10.1016/j.jmoldx.2017.01.011.

About the Association for Molecular Pathology

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit http://www.amp.org. Follow AMP on Twitter: @AMPath

Media Contact

Andrew Noble
[email protected]
415-722-2129
@ampath

http://www.amp.org/

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Enzalutamide vs. Abiraterone: A Taiwan Study Insight

October 7, 2025

Study Reveals GLP-1 Agonists Present New Challenges for PET-CT Imaging

October 7, 2025

Linkage: Connect DNA Regulatory Peaks to Genes

October 7, 2025

Understanding Cassava Mosaic Disease in Burkina Faso

October 7, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    955 shares
    Share 382 Tweet 239
  • New Study Reveals the Science Behind Exercise and Weight Loss

    99 shares
    Share 40 Tweet 25
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    95 shares
    Share 38 Tweet 24
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    77 shares
    Share 31 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Enzalutamide vs. Abiraterone: A Taiwan Study Insight

Study Reveals GLP-1 Agonists Present New Challenges for PET-CT Imaging

Linkage: Connect DNA Regulatory Peaks to Genes

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.